Surpass discontinued
This article was originally published in The Tan Sheet
Executive Summary
Wrigley Healthcare Division will be dissolved after discontinuing sales of its Surpass antacid chewing gum March 28. "Despite its quality, Surpass...has not been able to build broad enough popularity with consumers needed to support a brand long-term," 1Wrigley's Web site notes. Healthcare division, which was created two years ago to support Surpass' launch, will be phased out by May, firm says, with employees rejoining parent company. Wrigley's R&D team will "continue to explore the delivery of functional benefits" through chewing gum, with a focus on indications such as throat and cough relief, dental benefits. Firm has attributed poor Surpass sales to difficulty in convincing consumers to switch from liquid/pill antacid forms to gum (2"The Tan Sheet" March 4, 2002, p. 6)...
You may also be interested in...
Surpass Antacid Gum Marketing Strategy Shift Planned By Wrigley
Wrigley Healthcare is modifying its marketing strategy for Surpass antacid gum to increase consumer trials of the product after its introduction resulted in lower than expected sales
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.